Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154


Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.

Mu X, Zhang Y, Qu X, Hou K, Kang J, Hu X, Liu Y.

Biomed Res Int. 2013;2013:726375. doi: 10.1155/2013/726375. Epub 2013 Mar 19.


Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Yang G, Yao Y, Zhou J, Zhao Q.

Oncol Rep. 2012 Jun;27(6):2066-72. doi: 10.3892/or.2012.1741. Epub 2012 Mar 22.


[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].

Li X, Qin N, Wang J, Yang X, Zhang X, Lv J, Wu Y, Zhang H, Nong J, Zhang Q, Zhang S.

Zhongguo Fei Ai Za Zhi. 2015 Dec;18(12):734-9. doi: 10.3779/j.issn.1009-3419.2015.12.04. Chinese.


In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.

Wang MC, Liang X, Liu ZY, Cui J, Liu Y, Jing L, Jiang LL, Ma JQ, Han LL, Guo QQ, Yang CC, Wang J, Wu T, Nan KJ, Yao Y.

Oncol Rep. 2015 Jan;33(1):239-49. doi: 10.3892/or.2014.3583. Epub 2014 Nov 3.


Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.

Feng S, Wang Y, Cai K, Wu H, Xiong G, Wang H, Zhang Z.

PLoS One. 2015 Oct 16;10(10):e0140794. doi: 10.1371/journal.pone.0140794. eCollection 2015.


Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.

Pal HC, Sharma S, Strickland LR, Agarwal J, Athar M, Elmets CA, Afaq F.

PLoS One. 2013 Oct 4;8(10):e77270. doi: 10.1371/journal.pone.0077270. eCollection 2013.


[Clinical Analysis of Icotinib on Beneficiary of 
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].

Jiang X, Wang W, Zhang Y.

Zhongguo Fei Ai Za Zhi. 2016 Apr 20;19(4):200-6. doi: 10.3779/j.issn.1009-3419.2016.04.04. Chinese.


[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].

Song Z, Yu X, Cai J, Shao L, Lin B, He C, Zhang B, Zhang Y.

Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):138-43. doi: 10.3779/j.issn.1009-3419.2013.03.04. Chinese.


[Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].

Wang M, Zhang L, Zhao X, Liu J, Chen Y, Wang C.

Zhonghua Zhong Liu Za Zhi. 2014 Sep;36(9):651-6. Chinese.


[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.

Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):689-93. doi: 10.3779/j.issn.1009-3419.2012.12.02. Chinese.


Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.

Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J.

Lung Cancer. 2011 Aug;73(2):195-202. doi: 10.1016/j.lungcan.2010.11.007. Epub 2010 Dec 8.


Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K.

Cancer Res. 2010 Dec 15;70(24):10402-10. doi: 10.1158/0008-5472.CAN-10-2438.


Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.

Pan H, Liu R, Li S, Fang H, Wang Z, Huang S, Zhou J.

Cell Biochem Biophys. 2014 Sep;70(1):553-8. doi: 10.1007/s12013-014-9955-y.


CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.

Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.

Lung Cancer. 2014 Aug;85(2):152-60. doi: 10.1016/j.lungcan.2014.05.024. Epub 2014 Jun 5.


Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.

Yao S, Zhi X, Wang R, Qian K, Hu M, Zhang Y.

Thorac Cancer. 2016 Sep;7(5):543-548. doi: 10.1111/1759-7714.12365. Epub 2016 Jun 13.


Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.

Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM.

Exp Cell Res. 2007 Apr 15;313(7):1361-72. Epub 2007 Feb 3.


[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].

Zhou Y, Zhang S, Li K, Li QW, Zhou FZ, Li ZY, Ma H, Dong XR, Liu L, Wu G, Meng R.

Zhonghua Zhong Liu Za Zhi. 2016 Feb;38(2):100-4. doi: 10.3760/cma.j.issn.0253-3766.2016.02.005. Chinese.


Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.

Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.

Adv Med Sci. 2011;56(2):275-84. doi: 10.2478/v10039-011-0043-x.


Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.

Gao Z, Chen W, Zhang X, Cai P, Fang X, Xu Q, Sun Y, Gu Y.

Biomed Pharmacother. 2013 Jun;67(5):351-6. doi: 10.1016/j.biopha.2013.03.012. Epub 2013 Apr 2.


Supplemental Content

Support Center